The relapse rate after a first episode of schizophrenia is high, often due to non-adherence with medication. Long-acting injections of antipsychotics (LAI) are used to promote adherence to medication.
Objective:
To review the literature on the use of LAIs in first-episode and early schizophrenia.
Method:
A systematic electronic search of all original data containing peer-reviewed studies published in English using EMBASE, MEDLINE, Cochrane and PsychINFO from the onset of records. Reference lists from retrieved articles were examined for further relevant studies.
Results:
Ten studies were identified: two cohort studies; three randomised controlled trials; and five open studies. These studies, although limited, demonstrated the effectiveness of LAI in early schizophrenia. Seven of the 10 studies had risperidone long-acting injection as the only LAI.
Conclusion:
LAIs may be useful in the treatment of early schizophrenia in terms of symptom control and relapse reduction, particularly if chosen by the patient or when medication adherence is a priority. There is a need for a large-scale, randomised controlled trial comparing oral and LAI antipsychotics to assess long-term outcomes.
AndreasenNCCarpenterWTJrKaneJM. (2005) Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry162: 441–449.
2.
BartzokisGLuPHAmarCP. (2011) Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory. Schizophrenia Research132: 35–41.
3.
BirchwoodMToddPJacksonC (1998) Early intervention in psychosis. The critical period hypothesis. British Journal of Psychiatry. Supplement172: 53–59.
4.
ChatterjeeAChakosMKoreenA. (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. American Journal of Psychiatry152: 1724–1729.
5.
ColdhamELAddingtonJAddingtonD (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica106: 286–290.
6.
DavisJMMatalonLWatanabeMD. (1994) Depot antipsychotic drugs. Place in therapy. Drugs47: 741–773.
7.
EmsleyRMedoriRKoenL. (2008) Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study. Journal of Clinical Psychopharmacology28: 210–213.
8.
GlazerWM (2007) The depot paradox. Behavioral Healthcare27: 44–46.
9.
HaddadPMTaylorMNiazOS (2009) First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. British Journal of Psychiatry. Supplement52: S20–28.
10.
HeresSReichhartTHamannJ. (2011) Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. European Psychiatry26: 297–301.
11.
HogartyGESchoolerNRUlrichR. (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry36: 1283–1294.
12.
HorKTaylorM (2010) Suicide and schizophrenia: A systematic review of rates and risk factors. Journal of Psychopharmacology24: 81–90.
13.
JohnsonDA (2009) Historical perspective on antipsychotic long-acting injections. British Journal of Psychiatry. Supplement52: S7–12.
14.
KaneJMGarcia-RiberaC (2009) Clinical guideline recommendations for antipsychotic long-acting injections. British Journal of Psychiatry. Supplement52: S63–67.
15.
KaneJMRifkinAQuitkinF. (1982) Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry39: 70–73.
16.
KeithSJPaniLNickB. (2004) Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatric Services55: 997–1005.
17.
KeksNAInghamMKhanA. (2007) Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. British Journal of Psychiatry191: 131–139.
18.
KimBLeeSHChoiTK. (2008) Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting. Progress in Neuro-psychopharmacology and Biological Psychiatry32: 1231–1235.
19.
LasserRABossieCAZhuY. (2007) Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Annals of Clinical Psychiatry19: 65–71.
20.
MackayKTaylorMPatelMX (2011) Medication adherence and patient choice in mental health. British Journal of Hospital Medicine72: 6–7.
21.
MollerHJLlorcaPMSacchettiE. (2005) Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology20: 121–130.
22.
NapryeyenkoOBurbaBMartinezG. (2010) Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures. Journal of Clinical Psychopharmacology30: 200–202.
23.
National Institue of Clinical Excellence (NICE) (2009) NICE CG82. Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. London: NICE.
24.
ParelladaE (2006) Clinical experience and management considerations with long-acting risperidone. Current Medical Research and Opinion22: 241–255.
25.
ParelladaEAndrezinaRMilanovaV. (2005) Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. Journal of Psychopharmacology19: 5–14.
26.
PatelMXTaylorMDavidAS (2009) Antipsychotic long-acting injections: Mind the gap. British Journal of Psychiatry. Supplement52: S1–4.
27.
RobinsonDGWoernerMGAlvirJM. (1999) Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry156: 544–549.
28.
RosenheckRAKrystalJHLewR. (2011) Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine364: 842–851.
29.
SameleCLawton-SmithSWarnerL. (2007) Patient choice in psychiatry. British Journal of Psychiatry191: 1–2.
30.
ShajahanPSpenceETaylorM. (2010) Comparison of the effectiveness of depot antipsychotics in routine clinical practice. The Psychiatrist34: 273–279.
31.
StrassnigMMiewaldJKeshavanM. (2007) Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis. Schizophrenia Research93: 90–98.
32.
TaylorD (2009) Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review. British Journal of Psychiatry. Supplement52: S13–19.
33.
TiihonenJHaukkaJTaylorM. (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry168: 603–609.
34.
TiihonenJWahlbeckKLonnqvistJ. (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study. British Medical Journal333: 224.
35.
WeidenPJBuckleyPFGrodyM (2007) Understanding and treating ‘first-episode’ schizophrenia. The Psychiatric Clinics of North America30: 481–510.
36.
WeidenPJSchoolerNRWeedonJC. (2009) A randomised controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: Initial adherence outcome. Journal of Clinical Psychiatry70: 1397–1406.
